CATAFLAM 25 Milligram Coated Tablets

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
24-04-2024
Tabia za bidhaa Tabia za bidhaa (SPC)
24-04-2024

Viambatanisho vya kazi:

DICLOFENAC POTASSIUM

Inapatikana kutoka:

Novartis Pharmaceuticals UK Ltd

INN (Jina la Kimataifa):

DICLOFENAC POTASSIUM

Kipimo:

25 Milligram

Dawa fomu:

Coated Tablets

Dawa ya aina:

Product subject to prescription which may be renewed (B)

Idhini hali ya:

Authorised

Idhini ya tarehe:

0000-00-00

Tabia za bidhaa

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Cataflam 25mg Coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 25mg diclofenac potassium.
Each tablet also contains 45mg sucrose.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Coated Tablet (Tablet).
Circular, biconvex, pale red sugar coated tablet approximately 7.7mm diameter imprinted “CG” on one side and “DD”
on the other.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Short-term treatment of all grades of pain and inflammation in the following acute conditions:
Post traumatic pain, inflammation and swelling, e.g. due to sprains.
Acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendonitis, tenosynovitis,
bursitis.
Post-operative pain, inflammation and swelling, e.g. following dental or orthopaedic surgery.
Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis and associated
menorrhagia.
Migraine attacks.
Acute gout.
Painful syndromes of the vertebral column.
Non-articular rheumatism.
As an adjuvant in severe painful inflammatory infections of the ear, nose or throat, e.g. pharyngotonsillitis, otitis.
In keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as
appropriate. Fever alone is not an indication.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control
symptoms (see section 4.4).
The tablets should be swallowed whole with liquid, preferably before meals, and must not be divided or chewed.
ADULTS
The total daily dose should generally be divided in 2 to 3 doses.
In primary dysmenorrhoea, the daily dose should be individually 
                                
                                Soma hati kamili